Genomic landscape of lung cancer in the young

• Autores: Ruiz-Mendoza, R, Galvez-Nino, M, Roque, K, Montes-gila, J, Nuñez, Mará, Raez, Luis, Sánchez-Gambetta, Sergio, Jaúregui, Sandra, Viale, Sandra, Smith, Edward S, Pinto, JA, Mas López, L
• Formato: artículo
• Fecha de Publicación: 2022
• Institución: Instituto Nacional de Enfermedades Neoplásicas
• Repositorio: INEN-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.inen.sld.pe:20.500.14703/298
• Enlace del recurso: https: //doi.org/10.3389/fonc.2022.910117; https://hdl.handle.net/20.500.14703/298
• Nivel de acceso: acceso abierto
• Materia: genomic alterations; genomic profiling; lung cancer; non-small cell lung cancer; tumor mutational burden; https://purl.org/pe-repo/ocde/ford#3.02.21

Background: Lung cancer in the young is a rare entity of great interest due to the high frequency of targetable mutations. In this study, we explored the genomic landscape of non-small cell lung cancer (NSCLC) in young patients and compared it with genetic alterations in older patients. Methods: Comparative study of the genomic profile of NSCLC young (≤40 years old) vs older patients (>40 years old) from Instituto Nacional de Enfermedades Neoplásicas (INEN) in Lima, Peru. Archival paraffin-embedded tumor samples were profiled with FoundationOne CDx assay to identify short variants alterations (insertions and deletions), copy number variations (CNV), tumor mutational burden and microsatellite instability in 324 driver genes and rearrangements in 28 commonly rearranged genes. A targetable alteration was defined as any alteration in a driver oncogene for which an FDA approved therapy existed at the time of study enrollment. Results: Overall, 62 tumors were profiled, 32 from young and 30 from older patients. All clinicopathological features (smoking status, clinical stage, and histology) were similar between groups, except for gender (65.6% of females in the younger group vs 40% in the older group, P=0.043). At least one actionable mutation was present in 84.4% and 83.3% in younger and older patients, respectively. Alteration rates in the main genes were: BRAF, 3.1%(n=1) vs 0% EGFR, 46.9% (n=15) vs 43.3% (n=13) ERBB2, 12.5% (n=4) vs 16.7% (n=5) KRAS, 15.6% (n=5) vs 16.7% (n=5) ALK, 6.3% (n=2) vs 3.3% (n=1) RET, 0.0% vs 3.3% (n=1) RET, 0.0% vs 3.3% (n=1) ROS1, 3.1% (n=1) vs 3.3% (n=1) NTRK1, 0.0% vs 3.3% (n=1) and MET, 3.1% (n=1) vs 13.3% (n=4). Mean TMB was 4.04 Mut/Mb (SD ± 3.98) for young vs 8.06 Mut/Mb (SD ± 9.84) for older patients (P=0.016). There were not significant differences in CNV, frequency of gene rearrangements, or microsatellites instability. Conclusion: NSCLC in the young in our cohort was characterized by a high frequency of actionable genetic aberrations and a low TMB, which was also true for our older patients. The enrichment of actionable mutations in young patients described in other reports might be attributed to differences in the etiology and clinicopathological characteristics between younger and older patients and therefore not be applicable to all populations.